Wayne Clark, MD
Neurology · Portland, ORNPI 1356357958
Payments from drug & device makers
Across 452 payments — averaging $1640.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$313K
- Genentech, Inc.$190K
- E.r. Squibb & Sons, L.L.C.$122K
- Ceribell, Inc.$46K
- Daiichi Sankyo Inc.$25K
- Merck$23K
- plus $22K from 2 others
Across 3 payments — averaging $717.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$2K
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 314 | $312,765 |
| Genentech, Inc. | 23 | $190,248 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121,824 |
| Ceribell, Inc. | 1 | $46,138 |
| Daiichi Sankyo Inc. | 101 | $25,280 |
| Merck | 10 | $23,490 |
| Biogen | 1 | $19,418 |
| Medical Device Business Services, Inc. | 1 | $2,200 |
How this compares
$741,362 in reported general payments places this provider in the 95th percentile of 228 neurology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $10,924 |
| Cilostazol | 11 | $239 |
| ClopidogrelClopidogrel Bisulfate | 14 | $71 |
Paid to pharmacies, not to this prescriber.
Other neurology in Portland
- Stanley CohanPortland$3.9M
- Kyle SmootPortland$3.2M
- Aimee PiercePortland$3M
- Chafic KaramPortland$2.8M
- Prakash AmbadyPortland$2.7M
- Michael MegaPortland$2.5M
- Jeffrey KayePortland$1.5M
- Nizar ChahinPortland$1.4M
- Matthew BrodskyPortland$1.3M
- Richard RosenbaumPortland$589K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.